Medical worker Robert Gilbertson holds an injection with the Moderna Covid-19 vaccine.
APU Gomes | Agence France-Presse | Getty Images
One analyst said that biotech and pharmaceutical company Moderna, a leading developer of coronavirus vaccines, has the potential to reach a market capitalization of more than $ 100 billion.
When asked about our Mordana’s blue sky scenario, Who found his Coronavirus vaccine to be 94% effective in preventing serious Covid infectionAlready working on a booster dose to deal with the variable debuting in South Africa, sales paths of similar companies have shown what Moderna can experience for a future, Hartag Singh, managing director and chief biotechnology analyst at Oppenheimer, told CNBC Thursday.
“What we’re doing is directing people to other companies in the biotechnology sector that peaked or peaked when they launched their first batch of products. AlexionAnd the Regeneron And the VertexCurrently, it has peaked mainly at about ten times future sales, and future sales three to five years.
“I think with the modernity of our Coronavirus vaccine franchise, they also started developing the flu vaccines that will be on the market in the next two years … You know, we can see a $ 10 billion concession five to seven years from now. Times on that, you can do the math, and then it’s a company with a market capital of over $ 100 billion, ”he told CNBC’s” Street Signs Europe “. Its market value is currently just over $ 57 billion.
ModernThe company’s shares rose 3% in pre-market trading Thursday, as fourth-quarter revenues of $ 571 million significantly exceeded its estimate of $ 318.9 million, compared to $ 14 million for the fourth quarter of 2019.
It also projected $ 18.4 billion in Covid-19 vaccine sales in 2022, after it brought in $ 199.87 million in Covid-19 vaccine sales in the fourth quarter. However, the company reported a quarterly loss in equities of 69 cents, more than 35 percent of the loss analysts had expected.
In the earnings statement, CEO Stefan Bancel said that 2020 was a historic year for our supplier and that 2022 would be a “turning year” for the company.
“We previously thought mRNA would lead to approved drugs, and we were constrained in our ambitions by the need to regularly raise capital and retain several years of cash to manage financing risks. We now know that mRNA vaccines can be very effective and licensed to use, and we are a commercial company to generate the flow. Cash, “he said.
“We plan to accelerate and significantly increase our investment in science and grow our development pipeline faster. By implementing our priorities for 2022, we will further our mission of fulfilling the promise of mRNA science to create a new generation of transformative drugs for patients. This is just the beginning.”
The pharmaceutical company announced Wednesday that Trials of a new booster for the Covid-19 vaccine are scheduled to begin, Designed to provide better protection against a new type of virus that was first detected in South Africa. The biotech company said it shipped doses of the shot to the US National Institutes of Health for testing.
The current vaccine dose from Moderna elicits a weaker immune response against the South African strain of the virus, which was found to be more contagious than other variants, although the company said that the antibodies in patients remain higher than levels that would be expected to be protective against the virus.
“Our modernity is committed to making as many updates to our vaccine as necessary so that the epidemic is brought under control,” Bancel said in a press release. “We hope to demonstrate that booster doses, if needed, can be done at lower dosage levels, which will allow us to offer more doses to the global community in late 2022 and 2022 if needed.”
Separately, the company also announced Wednesday that it expects to produce up to 700 million doses in 2022 and 1.4 billion doses of the Covid-19 vaccine in 2022, assuming the vaccine will be administered at its current level of 100 micrograms.
If the vaccine proves to be effective at a lower dose level, the company said it could provide up to 2.8 billion doses in 2022. Moderna has struck a deal with the US government to supply 300 million doses.
Disclaimer: Hartag Singh does not own any shareholdings in Moderna Corporation.
– CNBC’s Berkeley Lovelace contributed to writing this story.